


PRODUCT INFORMATION



Regorafenib

Item No. 18498

CAS Registry No.: 755037-03-7
Formal Name: 4-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide
Synonym: BAY 73-4506
MF: C₂₁H₁₅ClF₄N₄O₃
FW: 482.8
Purity: ≥98%
UV/Vis.: λ_{max}: 263 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Regorafenib is supplied as a crystalline solid. A stock solution may be made by dissolving the regorafenib in the solvent of choice, which should be purged with an inert gas. Regorafenib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of regorafenib in ethanol is approximately 14 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Regorafenib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, regorafenib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Regorafenib has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity.¹ It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ with IC₅₀ values of 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively. Regorafenib also inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC₅₀s = 28, 46, 202, and 311 nM, respectively) as well as other kinases.¹⁻³ *In vivo*, regorafenib (10 mg/kg) reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models.¹ It also reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models. Formulations containing regorafenib have been used in the treatment of advanced gastrointestinal stromal tumors and metastatic colorectal cancer.

References

1. Wilhelm, S.M., Dumas, J., Adnane, L., *et al.* Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. *Int. J. Cancer* **129**(1), 245-255 (2011).
2. Uitdehaag, J.C.M., de Roos, J.A.D.M., van Doornmalen, A.M., *et al.* Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. *PLoS One* **9**(3), 1-13 (2014).
3. Ravi, S. and Singal, A.K. Regorafenib: An evidence-based review of its potential in patients with advanced liver cancer. *Core Evid.* **9**, 81-87 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/24/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM